Trials / Completed
CompletedNCT00286247
Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Introgen Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A maximum of 60 subjects will be enrolled in the trial. It is a non-randomized, open label, single center study. All subjects undergo INGN 201 injection and IV chemotherapy: doxorubicin and docetaxel. This is done on the first 2 days of a 3-week cycle. After completion of 4 to 6 cycles, the subject either proceeds to surgery if the tumors respond to therapy, or goes off study if there is no tumor response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | INGN 201 |
Timeline
- First posted
- 2006-02-03
- Last updated
- 2008-04-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00286247. Inclusion in this directory is not an endorsement.